A group of scientists, led by Beth Israel Deaconess Medical Center (BIDMC) immunologist Dan H. Barouch, MD, PhD, now report that a candidate COVID-19 vaccine developed at BIDMC in collaboration with Johnson and Johnson (NYSE: JNJ) raised neutralising antibodies and robustly protected non-human primates against SARS-CoV-2, the virus that causes COVID-19.
Bioqual has been engaged in development of in-vivo testing programs and has been extensively involved in research efforts to develop vaccines and therapies against emerging diseases including AIDS, Hepatitis, Zika, Chikungunya and many others.
The company is now focused on COVID-19 research and is positioned to play an important role in the development of successful vaccines and therapies against this epidemic.
Bruker demonstrates advancements in 4D-Proteomics at US HUPO
Mitem Pharma acquires Flisint rights from Sanofi to address rare infectious disease
Audientes partners with Audivista to expand hearing solutions in Middle East and North Africa
Benuvia Operations signs licensing deal with Avernus Pharma
Benuvia Operations signs licensing and supply agreements with Medra Brasil Medicamentos
Castle Biosciences to present data on Melanoma tests at ASDP Annual Meeting
Alchemy partners with PatchRx to improve HIV medication adherence
Gilead expands global access to lenacapavir for HIV prevention